These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 20505798)

  • 1. Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands.
    Christiaans I; Nannenberg EA; Dooijes D; Jongbloed RJ; Michels M; Postema PG; Majoor-Krakauer D; van den Wijngaard A; Mannens MM; van Tintelen JP; van Langen IM; Wilde AA
    Neth Heart J; 2010 May; 18(5):248-54. PubMed ID: 20505798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy.
    Girolami F; Olivotto I; Passerini I; Zachara E; Nistri S; Re F; Fantini S; Baldini K; Torricelli F; Cecchi F
    J Cardiovasc Med (Hagerstown); 2006 Aug; 7(8):601-7. PubMed ID: 16858239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of a large duplication mutation in the myosin-binding protein C3 gene in a case of hypertrophic cardiomyopathy.
    Meyer T; Pankuweit S; Richter A; Maisch B; Ruppert V
    Gene; 2013 Sep; 527(1):416-20. PubMed ID: 23816408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetics of hypertrophic cardiomyopathy in eastern Finland: few founder mutations with benign or intermediary phenotypes.
    Jääskeläinen P; Miettinen R; Kärkkäinen P; Toivonen L; Laakso M; Kuusisto J
    Ann Med; 2004; 36(1):23-32. PubMed ID: 15000344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel deletions in MYH7 and MYBPC3 identified in Indian families with familial hypertrophic cardiomyopathy.
    Waldmüller S; Sakthivel S; Saadi AV; Selignow C; Rakesh PG; Golubenko M; Joseph PK; Padmakumar R; Richard P; Schwartz K; Tharakan JM; Rajamanickam C; Vosberg HP
    J Mol Cell Cardiol; 2003 Jun; 35(6):623-36. PubMed ID: 12788380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nationwide study on hypertrophic cardiomyopathy in Iceland: evidence of a MYBPC3 founder mutation.
    Adalsteinsdottir B; Teekakirikul P; Maron BJ; Burke MA; Gudbjartsson DF; Holm H; Stefansson K; DePalma SR; Mazaika E; McDonough B; Danielsen R; Seidman JG; Seidman CE; Gunnarsson GT
    Circulation; 2014 Sep; 130(14):1158-67. PubMed ID: 25078086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands.
    Alders M; Jongbloed R; Deelen W; van den Wijngaard A; Doevendans P; Ten Cate F; Regitz-Zagrosek V; Vosberg HP; van Langen I; Wilde A; Dooijes D; Mannens M
    Eur Heart J; 2003 Oct; 24(20):1848-53. PubMed ID: 14563344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of mutations in symptomatic patients with hypertrophic cardiomyopathy in Taiwan.
    Chiou KR; Chu CT; Charng MJ
    J Cardiol; 2015 Mar; 65(3):250-6. PubMed ID: 25086479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations.
    Michels M; Soliman OI; Kofflard MJ; Hoedemaekers YM; Dooijes D; Majoor-Krakauer D; ten Cate FJ
    JACC Cardiovasc Imaging; 2009 Jan; 2(1):58-64. PubMed ID: 19356534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two founder mutations in the alpha-tropomyosin and the cardiac myosin-binding protein C genes are common causes of hypertrophic cardiomyopathy in the Finnish population.
    Jääskeläinen P; Heliö T; Aalto-Setälä K; Kaartinen M; Ilveskoski E; Hämäläinen L; Melin J; Nieminen MS; Laakso M; Kuusisto J; ; Kervinen H; Mustonen J; Juvonen J; Niemi M; Uusimaa P; Huttunen M; Kotila M; Pietilä M
    Ann Med; 2013 Feb; 45(1):85-90. PubMed ID: 22462493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new common mutation in the cardiac beta-myosin heavy chain gene in Finnish patients with hypertrophic cardiomyopathy.
    Jääskeläinen P; Heliö T; Aalto-Setälä K; Kaartinen M; Ilveskoski E; Hämäläinen L; Melin J; Kärkkäinen S; Peuhkurinen K; Nieminen MS; Laakso M; ; Kuusisto J
    Ann Med; 2014 Sep; 46(6):424-9. PubMed ID: 24888384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage.
    Viswanathan SK; Sanders HK; McNamara JW; Jagadeesan A; Jahangir A; Tajik AJ; Sadayappan S
    PLoS One; 2017; 12(11):e0187948. PubMed ID: 29121657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two cases of severe neonatal hypertrophic cardiomyopathy caused by compound heterozygous mutations in the MYBPC3 gene.
    Lekanne Deprez RH; Muurling-Vlietman JJ; Hruda J; Baars MJ; Wijnaendts LC; Stolte-Dijkstra I; Alders M; van Hagen JM
    J Med Genet; 2006 Oct; 43(10):829-32. PubMed ID: 16679492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.
    Sedaghat-Hamedani F; Kayvanpour E; Tugrul OF; Lai A; Amr A; Haas J; Proctor T; Ehlermann P; Jensen K; Katus HA; Meder B
    Clin Res Cardiol; 2018 Jan; 107(1):30-41. PubMed ID: 28840316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel correlations between the genotype and the phenotype of hypertrophic and dilated cardiomyopathy: results from the German Competence Network Heart Failure.
    Waldmüller S; Erdmann J; Binner P; Gelbrich G; Pankuweit S; Geier C; Timmermann B; Haremza J; Perrot A; Scheer S; Wachter R; Schulze-Waltrup N; Dermintzoglou A; Schönberger J; Zeh W; Jurmann B; Brodherr T; Börgel J; Farr M; Milting H; Blankenfeldt W; Reinhardt R; Özcelik C; Osterziel KJ; Loeffler M; Maisch B; Regitz-Zagrosek V; Schunkert H; Scheffold T;
    Eur J Heart Fail; 2011 Nov; 13(11):1185-92. PubMed ID: 21750094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The genetic basis of hypertrophic cardiomyopathy in cats and humans.
    Kittleson MD; Meurs KM; Harris SP
    J Vet Cardiol; 2015 Dec; 17 Suppl 1(Suppl 1):S53-73. PubMed ID: 26776594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the cardiac myosin-binding protein C gene are the predominant cause of familial hypertrophic cardiomyopathy in eastern Finland.
    Jääskeläinen P; Kuusisto J; Miettinen R; Kärkkäinen P; Kärkkäinen S; Heikkinen S; Peltola P; Pihlajamäki J; Vauhkonen I; Laakso M
    J Mol Med (Berl); 2002 Jul; 80(7):412-22. PubMed ID: 12110947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (β-Myosin Heavy Chain)- Versus MYBPC3 (Myosin-Binding Protein C)-Related Hypertrophic Cardiomyopathy.
    Weissler-Snir A; Hindieh W; Gruner C; Fourey D; Appelbaum E; Rowin E; Care M; Lesser JR; Haas TS; Udelson JE; Manning WJ; Olivotto I; Tomberli B; Maron BJ; Maron MS; Crean AM; Rakowski H; Chan RH
    Circ Cardiovasc Imaging; 2017 Feb; 10(2):. PubMed ID: 28193612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertrophic cardiomyopathy in a Portuguese population: mutations in the myosin-binding protein C gene.
    Cardim N; Perrot A; Santos S; Morgado P; Pádua M; Ferreira S; Reis RP; Monteiro C; Ferreira T; Correia JM; Osterziel KJ
    Rev Port Cardiol; 2005 Dec; 24(12):1463-76. PubMed ID: 16566405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life.
    Calore C; De Bortoli M; Romualdi C; Lorenzon A; Angelini A; Basso C; Thiene G; Iliceto S; Rampazzo A; Melacini P
    J Med Genet; 2015 May; 52(5):338-47. PubMed ID: 25740977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.